Key result
Elevated pulse pressure independently predicted all-cause mortality, cardiovascular events, and end-stage renal disease in Type 1 diabetes.
Why the study?
Do elevated pulse pressure and placental growth factor predict mortality, cardiovascular events, and progression to end-stage renal disease in patients with Type 1 diabetes?
Cohort (n=900)
Do elevated pulse pressure and placental growth factor predict mortality, cardiovascular events, and progression to end-stage renal disease in patients with Type 1 diabetes?
Elevated pulse pressure and placental growth factor independently and synergistically predict mortality, cardiovascular events, and end-stage renal disease in patients with Type 1 diabetes.
Answers are grounded in this paper and cite their sources.
May inform risk stratification in type 1 diabetes; hypothesis-generating and requires prospective trials before practice change.
AIMS: To evaluate whether pulse pressure alone or with placental growth factor as estimates of arterial stiffness and endothelial dysfunction, predicts mortality, cardiovascular disease and progression to end-stage renal disease in patients with Type 1 diabetes. METHODS: Prospective, observational study, median (range) follow-up 8 (0-13) years, 900 patients with Type 1 diabetes, 458 with diabetic nephropathy, mean ± SD age 44 ± 11 years. RESULTS: During follow-up, we recorded 178 (20%) all-cause deaths, 109 (12%) cardiovascular deaths, 213 (24%) cardiovascular events and 73 (16%) progressed to end-stage renal disease. Elevated pulse pressure predicted all-cause and cardiovascular mortality and cardiovascular events [Hazard Ratio (HR) (95% CI) per 10 mmHg increase]: HR 1.2 (1.1-1.3), 1.3 (1.2-1.5) and 1.2 (1.1-1.3), P<0.001 (adjusted for sex, age, HbA(1c) , cholesterol, diastolic blood pressure, creatinine, smoking, previous cardiovascular disease and nephropathy status). Furthermore, pulse pressure predicted the development of end-stage renal disease in patients with diabetic nephropathy: HR 1.2 (1.1-1.4), P=0.011 (adjusted for sex, age, HbA(1c) , cholesterol, diastolic blood pressure, previous cardiovascular disease and glomerular filtration rate). In a two-hit model, patients with pulse pressure and placental growth factor levels above the median vs. below the median had increased risk of all-cause and cardiovascular mortality, cardiovascular events and progression to end-stage renal disease: adjusted HRs 2.3 (1.2-4.2), 4.2 (1.6-11.0), 2.3 (1.3-4.1) and 3.5 (1.0-11.8),P<0.05. CONCLUSIONS: Elevated pulse pressure independently predicts mortality, cardiovascular events and progression to end-stage renal disease in patients with Type 1 diabetes. Placental growth factor adds to the predictive value of pulse pressure on cardiovascular and renal outcome.
No takes yet. Share an insight, caveat, or question.
Theilade et al. (2012) conducted a cohort in Type 1 diabetes (n=900). Elevated pulse pressure vs. Lower pulse pressure was evaluated on All-cause mortality (per 10 mmHg increase in pulse pressure) (HR 1.2, 95% CI 1.1-1.3, p=<0.001). Elevated pulse pressure independently predicted all-cause mortality, cardiovascular events, and end-stage renal disease in Type 1 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: